Suchergebnisse - "Immunosuppressive Agents"

1

Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis : A real-life observational study

enthalten in: Multiple sclerosis and related disorders | 2023

von Moreau, A. | Kolitsi, I. | Kremer, L. | +12

2

Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies

enthalten in: Journal of Korean medical science | 2020

von Ahn, G. | Suh, C. | Kim, Y. | +6

3

Clinical review report : indication : indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosusBelimumab (Benlysta) (GlaxoSmithKline Inc.)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, June 2020

CADTH common drug review

Version: Final.

4

Pharmacoeconomic review report : (UCB Canada Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapyCertolizumab pegol (Cimzia)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, January 2020

CADTH common drug review

Version: Final.

5

Pharmacoeconomic review report : indication: indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosusBelimumab (Benlysta) (GlaxoSmithKline Inc.)

Erschienen: Ottawa (ON), CADTH, June 2020

CADTH common drug review

Final (with redactions).

6

Clinical review report : (Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.) : indication : indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PEX) and immunosuppressive therapyCaplacizumab (Cablivi)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, October 2020

CADTH common drug review

Final (with redactions).

7

Second-line therapy for patients with relapsing-remitting multiple sclerosis : a review of guidelines

Erschienen: Ottawa (ON), CADTH, September 26, 2019

CADTH rapid response report: summary with critical appraisal

von Li, K. | Picheca, L.

8

Clinical review report : Cladribine (Mavenclad) (EMD serono)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, October 2018

CADTH common drug review

Version: Final with Redactions.

9

Belimumab treatment for adults with systemic lupus erythematosus : a review of clinical effectiveness, cost-effectiveness, and guidelines

Erschienen: Ottawa, CADTH, May 23, 2018

CADTH rapid response report: summary with critical appraisal

Version: 1.0.

von Chao, Y. | Adcock, L.

10

Pharmacokinetics and clinical outcomes of generic tacrolimus (Hexal) versus branded tacrolimus in de novo kidney transplant patients : a multicenter, randomized trial

enthalten in: Transplantation | 2017

von Arns, W. | Huppertz, A.

Filter & Sortierung